Dissecting the mechanisms of inflammation continues to be an important goal of modern biology. The expression of many common diseases results from inappropriate activation of inflammation, making this an important target for drug development. Inflammatory mechanisms are highly redundant and tissue injury is mediated by many mediators, acting in concert. Because of this, inhibiting an established inflammatory response is extremely difficult. It is particularly important to try to identify proximal events in inflammation in order to develop inhibitors which may be of clinical value. Progress in achieving this goal has been made recently in experiments that have taken advantage of the availability of 'knockout' mice with targeted mutations of either the gene encoding the antibody constant region (Fc) receptor or that encoding a neurotransmitter receptor.
The development of knockout mice with deficiencies of specific predetermined proteins offers a tool for exploring hierarchical pathways of inflammation. Sometimes, the study of such animals has confirmed what has previously been discovered from in vitro experiments. Often, however, investigators have been surprised by unexpected results, which fall into two general categories. The first, and most upsetting, of these categories is an absence of phenotype resulting from the deficiency of what the investigators dearly believed was the most important protein in the body. Such a result may be due to an unexpected redundancy of mechanisms, the failure to use an appropriate challenge to reveal a phenotype, or the biological unimportance of the protein in mice. The second, more immediately rewarding, category is the identification of an unexpected phenotype which may lead to the development of a new series of research questions.
Finding the relevant experimental challenge to reveal a phenotype may be extremely difficult. Humans with protein deficiencies are usually identified because the phenotype has been revealed by an appropriate environmental challenge. A good example of this is the way that deficiencies in proteins of the membrane attack complex of complement are associated with the development of neisserial meningitis and septicaemia [1] . The sole role in humans of the membrane attack complex of complement would appear to be that of host defence against Neisseriae, bacteria which can survive inside cells. The finding that humans lacking one of the protein components of the membrane attack complex are susceptible to neisserial infection is an excellent natural experimental demonstration of the requirement for extracellular lysis of these organisms by complement in host defence. In the absence of these data from humans, imagine an investigator faced with a mouse with no complement membrane attack complex, no phenotype and no clues. It would be very smart indeed to choose neisserial infection as the experimental challenge.
A valuable technique for triggering inflammation mediated by the immune system is the use of immune complexes. These consist of any combination of antibody with antigen. The binding of antibody to antigen promotes the removal of foreign antigens, the mounting of an adaptive immune response and the development of specific immunological memory. Immune complexes may also be an important cause of pathological tissue injury. This occurs in two situations. The first of these is when antigen persists because it is not cleared effectively following formation of immune complexes. Important examples of this are when the antigen is an autoantigen that cannot be removed from the body, or when the immune response is ineffective in controlling the infection and there is continuing production of antigens from the persistent infectious agent. The second circumstance in which immune complexes cause tissue injury is when the physiological clearance mechanisms are overwhelmed by formation of a large amount of immune complexes. A good example of this is serum sickness, which may follow injection of large amounts of poorly catabolized foreign antigen, such as streptokinase used to promote thrombolysis in the treatment of myocardial infarction [2] .
Immune complexes contain two types of potential ligand that may trigger inflammatory responses in tissues (Fig. 1) . The first is the Fc portion of the antibody, which may interact with Fc receptors on leucocytes, triggering their effector functions. Complement provides a further series of ligands, which may be further divided into two subtypes. The first are fixed to the complex and include C1q and covalently bound C3b and C4b and their cleavage products. These may stimulate inflammatory leucocytes through ligation of cell surface receptors by pathways very similar to those induced by ligation of Fc receptors. The second group of complement ligands are not fixed to the complexes and include the soluble anaphylatoxins, C3a and C5a, and the membrane attack complex, C5b-9. These augment the inflammatory response, in the case of the anaphylatoxins by ligation of G-protein-coupled receptors, and in the case of the membrane attack complex by perturbation of cell membranes. From this body of data it seemed probable that deficiency of complement or Fc receptors, or both, would abolish the inflammatory response mediated by immune complexes.
The inflammatory response known as the Arthus reaction has been used widely as a model to explore the pathogenesis of inflammatory injury to tissues induced by immune complexes. Early this century, Arthus described the local inflammatory response that follows the injection of antigen into the skin of sensitized animals [3] . This model can be varied -for example, one variant is the reverse passive Arthus reaction, in which antigen is injected intravenously and antibody subcutaneously. A further twist on this model is intrapulmonary immune complex formation, in which antigen is injected intravenously and antibody is introduced into the trachea; this results in formation of immune complexes across the alveolar wall. Each of these model reactions has recently been tested in knockout mice to explore the relative roles of complement and Fc receptors in the induction of inflammation.
In skin, a combination of new knock-out experiments [4, 5] and older data [6] show that the reverse passive Arthus reaction is dependent on both Fc-and complementmediated pathways [4] [5] [6] . In the new experiments [5] , depletion of complement using cobra venom factor did not significantly reduce the inflammatory response in wildtype mice. But, in mutant mice lacking the Fc receptor Fc␥RIII, the response was diminished to a variable degree which correlated inversely with the level of haemolytic complement expressed in individual animals [5] . Complete abolition of the response was only seen in the Fc␥RIII mutant animals following depletion of complement. These findings may be seen as confirmation of experiments performed using C5-deficient or complement-depleted mice, which showed that, at low concentrations of antibody,complement-dependent inflammatory pathways dominated, whereas at high antibody concentrations, complementindependent pathways were more apparent [6] .
The results from studies of the reverse passive Arthus reaction in the lung are broadly consistent with those in the skin, though in this case complement depletion or C5 deficiency seems to block the inflammatory response more effectively than it does in the skin [7] . The observation that C5 deficiency has some protective effect against the Arthus reaction in the lung [7] , as in the skin, implies a role for the anaphylatoxin C5a and/or the membrane attack complex in this inflammatory response. This has now been confirmed by experiments using two further mutant strains of mice, which have revealed an additional layer of complexity of the mechanisms of inflammation.
Intrapulmonary immune complex formation was explored in mice with targeted deletions of the either the substance P receptor (NK-1R) or C5a receptor gene [8] . The inflammatory response following intrapulmonary immune complex formation was absent in both NK-1R -/-and C5aR -/-mice. Which comes first in the inflammatory response, C5a or substance P? Levels of substance P and tumour necrosis factor-␣ (TNF-␣) were elevated following immune complex challenge in both the C5aR -/-and NK-1R -/-mice. This observation was used to argue that that Immune complexes trigger inflammation by ligation of Fc, C3 or anaphylatoxin (such as C5a) receptors on mast cells and leucocytes, such as neutrophils. The release of mediators from mast cells causes an increase in local vascular permeability, which facilitates the access of plasma proteins to tissues and thereby amplifies inflammation. the response to substance P occurs before C5 activation, but in the absence of data on C5a levels in the NK-1R -/-mice this conclusion is, while plausible, somewhat speculative. Whatever the hierarchy of the inflammatory cascade, these results show an important additional facet to the inflammatory response to immune complexesthe involvement of substance P, a neurotransmitter that is expressed by macrophages and mast cells, as well as Ctype nerve fibres.
What is the cell type responsible for triggering tissue injury in response to immune complexes in the Arthus reaction? Several lines of evidence support an important role for mast cells. A strain of mice lacking mast cells, because of a deficiency of stem cell factor, c-kit, showed a markedly reduced, though not abolished, reverse passive Arthus reaction [9] . These mice have now been reconstituted with mast cells derived from either wild-type animals or mutants deficient in the Fc receptor ␥ chain (Fc␥RIII) [10] . The Arthus response was only restored to normal in mice reconstituted with mast cells bearing Fc␥RIII, showing that immune complexes in this model trigger mast cells to release their mediators and cause inflammation by ligation of Fc␥RIII.
Several conclusions may be drawn from the first results of this latest phase of research on inflammation using knockout mice. First, the relative importance of different pathways of inflammation may vary according to the type of immune complex and its site of formation. The induction of inflammation is blocked, in some circumstances, by the absence of Fc receptors, and in others by a deficiency of complement or complement receptors. Second, the mast cell has been shown to play a pivotal role in the Arthus reaction, similar to the role this cell plays in anaphylactic reactions triggered by ligation of mast-cell-bound immunoglubulin E. Third, the exciting finding that deficiency of a neurotransmitter receptor blocks immune-complex-mediated inflammation in the lung opens up a new avenue of research into mechanisms of inflammation induced by antibodies. Neuroimmunology is alive and well.
